Literature DB >> 24681409

In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers.

George S Karagiannis1, Maria P Pavlou2, Punit Saraon3, Natasha Musrap4, Annie Xie5, Ihor Batruch6, Ioannis Prassas7, Apostolos Dimitromanolakis8, Constantina Petraki9, Eleftherios P Diamandis10.   

Abstract

Systemic mining of cancer exoproteome/secretome has emerged as a pivotal strategy for delineation of molecular pathways with mechanistic importance in cancer development, as well as the discovery of diagnostic/prognostic biomarkers. Although major advances in diagnostic and therapeutic management of colorectal cancer have been underscored in the last decade, this cancer still remains the second leading cause of cancer-related deaths in the developed world. Despite previous studies on deciphering the colorectal cancer exoproteome, such studies lack adequate depth and robustness due to technological limitations. Here, using a well-established LC-MS/MS method on an LTQ-Orbitrap mass spectrometer, we extensively delineated the exoproteome of 12 colon cancer cell lines. In total, 2979 non-redundant proteins were identified with a minimum of two peptides, of which ~62% were extracellular or cell membrane-bound, based on prediction software. To further characterize this dataset and identify clinical opportunities, first, we investigated overrepresented molecular concepts of interest via enrichment map analysis and second, we demonstrated translational importance of certain proteins, such as olfactomedin-4 and kallikrein-related peptidases-6 and -10, by investigating their expression levels in patient tissues and/or fluids. Overall, the present study details a comprehensive colorectal cancer exoproteome dataset, and may be used as future platform for biomarker discovery, and hypothesis-generating studies. BIOLOGICAL SIGNIFICANCE: This article represents one of the most extensive and comprehensive proteomic datasets regarding the secreted/extracellular proteome of colorectal cancer cell lines. The reported datasets may form a platform for a plethora of future, discovery-based or hypothesis-generating studies, attempting to either delineate putative cancer biomarkers for CRC, or elucidate questions of mechanistic importance (e.g. investigation of deregulated pathways for CRC progression).
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Enrichment map analysis; Exoproteome; Kallikrein-related peptidase; Olfactomedin-4; Proteomics

Mesh:

Substances:

Year:  2014        PMID: 24681409     DOI: 10.1016/j.jprot.2014.03.018

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  10 in total

1.  Development of a test to identify bladder cancer in the urine of patients using mass spectroscopy and subcellular localization of the detected proteins.

Authors:  Stephen W Wilz; Dong Liu; Chaoxu Liu; Jinghua Yang
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

2.  Retinoid Chemoprevention: Who Can Benefit?

Authors:  Rodica P Bunaciu; Andrew Yen
Journal:  Curr Pharmacol Rep       Date:  2015-04-15

3.  In-depth analysis of secretome and N-glycosecretome of human hepatocellular carcinoma metastatic cell lines shed light on metastasis correlated proteins.

Authors:  Xianyu Li; Jing Jiang; Xinyuan Zhao; Yan Zhao; Qichen Cao; Qing Zhao; Huanhuan Han; Jifeng Wang; Zixiang Yu; Bo Peng; Wantao Ying; Xiaohong Qian
Journal:  Oncotarget       Date:  2016-04-19

4.  Plasma N-glycans in colorectal cancer risk.

Authors:  Margaret Doherty; Evropi Theodoratou; Ian Walsh; Barbara Adamczyk; Henning Stöckmann; Felix Agakov; Maria Timofeeva; Irena Trbojević-Akmačić; Frano Vučković; Fergal Duffy; Ciara A McManus; Susan M Farrington; Malcolm G Dunlop; Markus Perola; Gordan Lauc; Harry Campbell; Pauline M Rudd
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

Review 5.  Proteomics approach and techniques in identification of reliable biomarkers for diseases.

Authors:  Raed Abdullah Alharbi
Journal:  Saudi J Biol Sci       Date:  2020-01-27       Impact factor: 4.219

6.  Plasma levels of OLFM4 in normals and patients with gastrointestinal cancer.

Authors:  Stine N Clemmensen; Anders J Glenthøj; Sara Heebøll; Hans Jørgen Nielsen; Claus Koch; Niels Borregaard
Journal:  J Cell Mol Med       Date:  2015-09-28       Impact factor: 5.310

7.  In-Depth Proteomic Analysis of the Hippocampus in a Rat Model after Cerebral Ischaemic Injury and Repair by Danhong Injection (DHI).

Authors:  Yiran Cui; Xin Liu; Xianyu Li; Hongjun Yang
Journal:  Int J Mol Sci       Date:  2017-06-24       Impact factor: 5.923

8.  The plasma peptides of ovarian cancer.

Authors:  Jaimie Dufresne; Pete Bowden; Thanusi Thavarajah; Angelique Florentinus-Mefailoski; Zhuo Zhen Chen; Monika Tucholska; Tenzin Norzin; Margaret Truc Ho; Morla Phan; Nargiz Mohamed; Amir Ravandi; Eric Stanton; Arthur S Slutsky; Claudia C Dos Santos; Alexander Romaschin; John C Marshall; Christina Addison; Shawn Malone; Daren Heyland; Philip Scheltens; Joep Killestein; Charlotte E Teunissen; Eleftherios P Diamandis; K W Michael Siu; John G Marshall
Journal:  Clin Proteomics       Date:  2018-12-21       Impact factor: 3.988

9.  The plasma peptides of breast versus ovarian cancer.

Authors:  Jaimie Dufresne; Pete Bowden; Thanusi Thavarajah; Angelique Florentinus-Mefailoski; Zhuo Zhen Chen; Monika Tucholska; Tenzin Norzin; Margaret Truc Ho; Morla Phan; Nargiz Mohamed; Amir Ravandi; Eric Stanton; Arthur S Slutsky; Claudia C Dos Santos; Alexander Romaschin; John C Marshall; Christina Addison; Shawn Malone; Daren Heyland; Philip Scheltens; Joep Killestein; Charlotte Teunissen; Eleftherios P Diamandis; K W M Siu; John G Marshall
Journal:  Clin Proteomics       Date:  2019-12-23       Impact factor: 3.988

Review 10.  Secretome Proteomic Approaches for Biomarker Discovery: An Update on Colorectal Cancer.

Authors:  Armando Cevenini; Stefania Orrù; Esther Imperlini
Journal:  Medicina (Kaunas)       Date:  2020-08-31       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.